Skip Navigation


Annals of Oncology Advance Access originally published online on October 30, 2006
Annals of Oncology 2007 18(3):601-602; doi:10.1093/annonc/mdl409
This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow All Versions of this Article:
18/3/601    most recent
mdl409v1
Right arrow E-letters: Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when E-letters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Search for citing articles in:
ISI Web of Science (3)
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Bossi, P
Right arrow Articles by Licitra, L
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Bossi, P
Right arrow Articles by Licitra, L
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

© 2006 European Society for Medical Oncology

letters to the editor

Previously irradiated areas spared from skin toxicity induced by cetuximab in six patients: implications for the administration of EGFR inhibitors in previously irradiated patients

The first 10% of the full text of this article appears below.

Skin toxicity induced by epidermal growth factor receptor (EGFR) inhibitors is well known, and indeed it is even debated whether it may mirror antitumor activity. In this report, we evaluate six patients, in whom the acneiform skin rash induced by cetuximab sharply spared previously irradiated areas.

Patient characteristics and treatment details are reported in Table 1. The interval between radiotherapy and cetuximab-based therapy varied from 3 to 68 months (median 15.5 months), while radiation doses ranged from 36 to 70 . . . [Full Text of this Article]

P Bossi1, C Liberatoscioli1, C Bergamini1, LD Locati1, S Fava2, G Rinaldi3, E Orlandi4, P Olmi4, E Tagliabue5, S Ménard5 and L Licitra1,*

1 Head and Neck Cancer Medical Oncology Unit, Istituto Nazionale per lo Studio e la Cura dei Tumori, Milan
2 Medical Oncology Unit, Ospedale Civile, Legnano
3 Medical Oncology Unit, Università degli Studi, Palermo
4 Radiotherapy Department
5 Department of Experimental Oncology, Istituto Nazionale per lo Studio e la Cura dei Tumori, Milan, Italy

* E-mail: lisa.licitra@istitutotumori.mi.it


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?